glp 1 news Medicare is about to cover GLP-1 drugs for weight loss. Here's what to know The growing availability of compounded

Notably, GLP-1RAs slow the transit time of the gastrointestinal (GI) tract and suppress appetite, which could displace nutrient intake and result in mineral and vitamin deficiencies

NPs play a key role in addressing these barriers, advocating for patients, and promoting informed, stigma-free discussions that support safe and equitable use

Obesity is considered as a cosmetic disease or a lack of willpower

Its very common for pharmaceutical companies to collect genetic data on their participants, she said

Image Credit: zimmytws / Shutterstock A recent review published in The Nurse Practitioner highlights the expanding clinical role of glucagon-like peptide-1 receptor agonists (GLP-1RAs), which have also drawn widespread media attention for their rapid weight-loss effects

GLP-1s and Addiction The authors of GLP-1 Therapeutics and Their Emerging Role in Alcohol and Substance Use Disorders: An Endocrinology Primer , appearing in October 2025 in JES, point out that the World Health Organization reported 890 million adults and 60 million children and adolescents had obesity in 2022 globally